

In re Application of N. Cashman and M. Lehto  
Application No. 10/568,729  
Filed February 17, 2006

Attorney Docket No. P31,382 USA  
July 10, 2006  
Page: 2

### Amendments to the Specification

(1) Please insert Pages 1 to 3 of the enclosed Sequence Listing after the Abstract and before the Figures in accordance with 37 C.F.R. §1.77(b).

(2) Please replace the paragraph on page 38, lines 23-27 with the following paragraph:

The invention contemplates the use of known antibodies as the binding agent including biotin-3F4 and 3F4 and 6H4 which recognize prion disease proteins. 3F4 reacts against the MKHV (SEQ ID NO:1) epitope and 6H4 reacts against the DYEDRYRE (SEQ ID NO:2) epitope. Additionally, 6E10 which recognizes Abeta, reacts against the EFRHDS (SEQ ID NO:3) epitope (residues 3-8).

(3) Please replace the paragraph on page 61, lines 18-20 with the following paragraph:

The five SOD1 sequences that meet these criteria are: 22QKESNG27 (SEQ ID NO:4); 51EDNTAGCTSA60 (SEQ ID NO:5); 74PKDEERHV81 (SEQ ID NO:6); 89ADKDG93 (SEQ ID NO:7); and 127GKGGNEQSTK136 (SEQ ID NO:8) (in **bold**: solvated side chains).

(4) Please replace the paragraphs on page 61, lines 28-32 with the following paragraph:

Electrostatic loop of human SOD1: Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr  
Lys Thr Gly Asn Ala Gly Ser (SEQ ID NO:9)

Zinc-binding loop of human SOD1: Asn Pro Leu Ser Arg Lys His Gly Gly Pro Lys  
Asp Glu Glu (SEQ ID NO:10)